1374645-63-2

Upstream product

• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 1736-31-8 ethyl 3-(4-fluorophenyl)propiolate 
• 87576-94-1 trimethylsilylmethyl azide 

Downstream Products

• 1374673-07-0 6-[5-(4-fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-pyridazine-3-carboxylic acid 
• 1374673-05-8 3-chloro-6-[5-(4-fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-pyridazine 
• 1374672-36-2 6-[5-(4-Fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-pyridazine-3-carboxylic acid (tetrahydro-pyran-4-yl)-amide 
• 1374672-35-1 6-[5-(4-fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-pyridazine-3-carboxylic acid ethyl ester 
• 1374645-69-8 5-[5-(4-Fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylic acid 
• 1374645-68-7 Methyl 5-[5-(4-fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylate 
• 1374645-67-6 3-[5-(4-fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-isoxazole-5-carboxylic acid 
• 1374645-66-5 Methyl 3-[5-(4-Fluoro-phenyl)-3-methyl-3H-[1,2,3]-triazol-4-ylmethoxy]-isoxazole-5-carboxylate 
• 1374645-53-0 5-[5-(4-Fluoro-phenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-2-methyl-2H-pyrazole-3-carboxylic acid (tetrahydro-pyran-4-yl)-amide 
• 1374645-52-9 3-[5-(4-fluoro-phenyl)-3-methyl-3H-[1,2,3]-triazol-4-ylmethoxy]-isoxazole-5-carboxylic acid (tetrahydro-pyran-4-yl)-amide 
• 1374645-65-4 [4-(4-fluorophenyl)-1-methyl-1H-1,2,3-triazol-5-yl]methanol 
• 1374645-64-3 [5-(4-fluoro-phenyl)-3-trimethylsilanylmethyl-3H-[1,2,3]triazol-4-yl]-methanol 
• 1374672-04-4 6-[5-(4-fluorophenyl)-3-methyl-3H-[1,2,3]triazol-4-ylmethoxy]-N-(tetrahydropyran-4-yl)-nicotinamide 
• 1374672-83-9 6-[5-(4-Fluoro-phenyl)-3-methyl-3H-[1,2,3]-triazol-4-ylmethoxy]-nicotinic acid 

Relevant academic research and scientific papers

NOVEL TRIAZOLE COMPOUNDS I

The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

NOVEL TRIAZOLE COMPOUNDS II

The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, u, v, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. The compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as pharmaceuticals.

TRIAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS

The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, u,v, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS

The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.